Immuneering Welcomes Dr. Thomas Schall as the New Chairman
Immuneering Corporation, a pioneering oncology company, has appointed Dr. Thomas J. Schall, Ph.D., as the new Chairman of its Board of Directors. This comes at a crucial moment for the company, which is dedicated to developing therapies designed to improve the lives of cancer patients.
Dr. Schall's Extensive Experience in the Biotech Sector
Dr. Schall is a well-respected figure in the biotechnology industry, boasting over three decades of experience in drug discovery and development. He previously served as the founder, CEO, and Chairman of ChemoCentryx, where his leadership led to the FDA approval of Tavneos, an innovative treatment for ANCA-associated vasculitis. Notably, ChemoCentryx was acquired by Amgen for approximately $4 billion, highlighting the significant impact of Dr. Schall's work in advancing medical therapies.
Strategic Vision for Immuneering's Future
Ben Zeskind, Ph.D., CEO of Immuneering, expressed enthusiasm about Dr. Schall's appointment, emphasizing his expertise in steering companies through the complexities of drug development, regulatory approval, and market launch. Zeskind stated that Dr. Schall's leadership will be pivotal as Immuneering advances its lead program, atebimetinib, through its late-stage development.
Upcoming Data Releases from Immuneering
Immuneering is anticipated to share updated clinical trial data from its ongoing Phase 2a study involving first-line pancreatic cancer patients. Results will be made available with a median follow-up period of nine months at an upcoming event, emphasizing the company's commitment to transparency and ongoing communication in its research endeavors.
Dr. Schall's Commitment to Patient-Centric Medicine
In his own words, Dr. Schall highlighted that his career has been centered around developing meaningful therapies for patients, which aligns closely with Immuneering's mission. He expressed honor in taking on the role of Chairman during this critical phase for the company and believes that their innovative approach has the potential to change expectations within the oncology landscape.
About Immuneering Corporation
Immuneering Corporation is focused on revolutionizing cancer treatment through its unique category of medicines called Deep Cyclic Inhibitors. The company's lead candidate, atebimetinib, represents a promising oral, once-daily therapy aimed at enhancing patient outcomes by targeting MEK pathways relevant to various tumors, including many pancreatic cancers. Immuneering not only works on this advanced candidate but also nurtures early-stage programs to broaden its impact in oncology.
Frequently Asked Questions
What is the significance of Dr. Schall's appointment?
Dr. Schall's appointment is crucial as he brings extensive experience in biotech and drug development, which will guide Immuneering's strategic direction.
What is atebimetinib?
Atebimetinib is Immuneering's lead product candidate designed to enhance the effectiveness and tolerability of cancer treatments, specifically targeting MEK pathways.
How does Immuneering position itself in the cancer therapy landscape?
Immuneering aims to redefine cancer treatments through innovative therapies aimed at high unmet needs within oncology.
What upcoming events should we look for from Immuneering?
The company plans to announce updated data from its Phase 2a trial on alternative therapies for pancreatic cancer soon.
Who can be contacted for media inquiries about Immuneering?
For media inquiries, Carson Creehan can be reached at 817-412-1096 or via email.
